As a biosynthetic precursor of polycyclic xanthone derivatives, lysoquinone-TH1 without the xanthone unit was found to inhibit phosphodiesterase 4 (PDE4) and had potential to treat PDE4-related chronic obstructive pulmonary diseases (Hofeditz et al., 2018). Here, PDE4A is linked to chronic obstructive pulmonary disease.